Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Dec;103(6):1893-901.
doi: 10.1016/0016-5085(92)91449-e.

Primary sclerosing cholangitis: refinement and validation of survival models

Affiliations

Primary sclerosing cholangitis: refinement and validation of survival models

E R Dickson et al. Gastroenterology. 1992 Dec.

Abstract

The natural history of primary sclerosing cholangitis was studied in 426 patients from five medical centers. The median follow-up time was 3.0 years (range, 0.01-16.6 years); 100 patients had died by the time of last follow-up. Survival analysis (Cox proportional-hazards regression) was used to identify the variables most useful in predicting survival of patients with primary sclerosing cholangitis. Serum bilirubin concentration, histological stage on liver biopsy, age, and the presence of splenomegaly were independent predictors of a high risk of dying. A mathematical model to predict survival of patients with primary sclerosing cholangitis (based on referral values of those predictors) was statistically validated using two methods. Confidence intervals for predicting patient-specific survival probabilities are also presented. This model to predict survival could be used to stratify participants in therapeutic trials, counsel patients and their families, decide on candidacy for and timing of liver transplantation, and provide mathematical controls for evaluating the efficacy of therapies for primary sclerosing cholangitis, including transplantation.

PubMed Disclaimer

Similar articles

Cited by

  • Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis.
    Gauss A, Sauer P, Stiehl A, Rupp C, Krisam J, Leopold Y, Kloeters-Plachky P, Stremmel W, Gotthardt D. Gauss A, et al. Medicine (Baltimore). 2016 Apr;95(17):e3510. doi: 10.1097/MD.0000000000003510. Medicine (Baltimore). 2016. PMID: 27124059 Free PMC article.
  • Primary sclerosing cholangitis: overview and update.
    Mendes F, Lindor KD. Mendes F, et al. Nat Rev Gastroenterol Hepatol. 2010 Nov;7(11):611-9. doi: 10.1038/nrgastro.2010.155. Epub 2010 Oct 12. Nat Rev Gastroenterol Hepatol. 2010. PMID: 20938459 Review.
  • The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE) Index: A Prognostic Tool for Children.
    Deneau MR, Mack C, Perito ER, Ricciuto A, Valentino PL, Amin M, Amir AZ, Aumar M, Auth M, Broderick A, DiGuglielmo M, Draijer LG, Tavares Fagundes ED, El-Matary W, Ferrari F, Furuya KN, Gupta N, Hochberg JT, Homan M, Horslen S, Iorio R, Jensen MK, Jonas MM, Kamath BM, Kerkar N, Kim KM, Kolho KL, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Martinez M, Miethke A, Miloh T, Mogul D, Mohammad S, Mohan P, Moroz S, Ovchinsky N, Palle S, Papadopoulou A, Rao G, Rodrigues Ferreira A, Sathya P, Schwarz KB, Shah U, Shteyer E, Singh R, Smolka V, Soufi N, Tanaka A, Varier R, Vitola B, Woynarowski M, Zerofsky M, Zizzo A, Guthery SL. Deneau MR, et al. Hepatology. 2021 Mar;73(3):1074-1087. doi: 10.1002/hep.31393. Epub 2020 Dec 19. Hepatology. 2021. PMID: 32464706 Free PMC article.
  • Hepatobiliary complications of inflammatory bowel disease.
    Lichtenstein DR. Lichtenstein DR. Curr Gastroenterol Rep. 2011 Oct;13(5):495-505. doi: 10.1007/s11894-011-0213-9. Curr Gastroenterol Rep. 2011. PMID: 21773706 Review.
  • Primary sclerosing cholangitis.
    Silveira MG, Lindor KD. Silveira MG, et al. Can J Gastroenterol. 2008 Aug;22(8):689-98. doi: 10.1155/2008/824168. Can J Gastroenterol. 2008. PMID: 18701947 Free PMC article. Review.

LinkOut - more resources